Achaogen raises $26 million in series B financing

By Lisa Kerner

Charlotte, N.C., Oct. 10 - Achaogen, Inc. closed a series B round of financing, raising more $26 million dollars to advance its lead antibacterial program through clinical proof of concept and to advance other programs.

New investor Domain Venture Partners led the round, joined by Achaogen's series A investors 5AM Ventures, ARCH Venture Partners, Venrock Associates and Versant Ventures.

Bob More of Domain will join Achaogen's board of directors.

Achaogen, based in South San Francisco, Calif., develops novel antibacterial compounds.

Issue:	Achaogen, Inc.
Issue:	Series B financing
Amount:	$26 million plus
Investors:	Domain Venture Partners (lead), 5AM Ventures, ARCH Venture Partners, Venrock Associates, Versant Ventures
Announcement date:	Oct. 10

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.